Ultragenyx Pharmaceutical (NASDAQ:RARE) Director Corazon (Corsee) Sanders Sells 2,000 Shares of Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) Sanders sold 2,000 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the transaction, the director owned 21,095 shares of the company’s stock, valued at approximately $528,429.75. This represents a 8.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE opened at $25.38 on Tuesday. The stock’s 50-day simple moving average is $24.04 and its 200 day simple moving average is $25.02. The company has a market cap of $2.50 billion, a P/E ratio of -4.15 and a beta of 0.37. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.29 and a 52-week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The company had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.19 million. During the same quarter in the previous year, the company posted ($1.57) EPS. The business’s revenue was down 2.2% on a year-over-year basis. As a group, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -4.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several hedge funds have recently bought and sold shares of the company. Parallel Advisors LLC lifted its stake in Ultragenyx Pharmaceutical by 778.4% in the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,440 shares during the last quarter. Amundi acquired a new stake in Ultragenyx Pharmaceutical in the 1st quarter valued at about $318,000. EverSource Wealth Advisors LLC lifted its stake in Ultragenyx Pharmaceutical by 573.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 1,845 shares during the last quarter. California State Teachers Retirement System lifted its stake in Ultragenyx Pharmaceutical by 25.6% in the 1st quarter. California State Teachers Retirement System now owns 104,650 shares of the biopharmaceutical company’s stock valued at $2,192,000 after purchasing an additional 21,313 shares during the last quarter. Finally, Eagle Health Investments LP acquired a new stake in Ultragenyx Pharmaceutical in the 1st quarter valued at about $18,522,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. HC Wainwright dropped their target price on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Barclays dropped their target price on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, April 29th. Canaccord Genuity Group dropped their target price on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Cantor Fitzgerald upped their target price on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the stock an “overweight” rating in a report on Thursday, May 21st. Finally, Wells Fargo & Company upped their target price on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $59.56.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.